Company intelligence / Profile preview

Cellarant

San Carlos, California, United States

Ownership: Private
Development stage: Other

Overview

Cellerant's lead product CLT-008 is in two Phase 1 clinical trials for hematological malignancies. The company has presented Phase 2 results showing CLT-008 significantly reduces risk of infections in AML patients undergoing standard induction chemotherapy.

Therapeutic areas: HematologyOncology
Modalities: Antibody-drug conjugateStem cell therapyMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Cellarant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellarant.

Explore the full profile